https://www.cancernetwork.com/view/t-dxd-yields-consistent-results-in-her2-low-advanced-breast-cancer
0
0
10/21/23 at 4:45pm
Organization
Cancernetwork.com
Author
Ariana Pelosci
41 words
0
Comments
Results from an updated analysis of the DESTINY-Breast04 trial indicate an efficacy improvement when trastuzumab deruxtecan monotherapy is used for patients with HER2-low metastatic breast cancer.
You are the first to view
Create an account
or login to join the discussion